Deerfield, Ill., July 25, 2003 -- Baxter Healthcare Corporation announced today that the U.S. Food and Drug Administration (FDA) has approved ADVATE (Antihemophilic Factor (Recombinant), ...
A post-hoc analysis has identified an interrelation between peak levels of factor VIII (:FVIII) in a patient’s body in the first few hours after infusion and the efficiency of prophylaxis treatment in ...
June 13, 2006 -- The U.S. Food and Drug Administration (FDA) has approved a 2000-IU (5-mL) dose for antihemophilic factor VIII [recombinant] infusion; and an expanded indication for infliximab ...
New findings from a post-hoc analysis of the ADVATE prophylaxis study presented at ISTH (PB 4.39-1) indicate important insights on the efficacy of prophylaxis treatment by closely monitoring the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results